LncRNA MFI2-AS1 is in clinical trials for use as a diagnostic biomarker for kidney cancer [105], and lncRNAs UCA1 and WRAP53 are in clinical trials for use as diagnostic biomarkers for hepatocellular carcinoma [106]. Here, WRAP53 is linked to kidney cancer.